This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights CF PharmTech’s HKEX listing with a 227% grey market premium, Eccogene’s HKEX IPO filing at a US$500M valuation, Zenas Bio’s US$2B licensing deal with InnoCare, and Nuruit Medical’s RMB 800M Series D financing. Clinical updates include Henlius’s serplulimab Phase III success in gastric cancer, Sino Biopharma’s positive Phase II results for COPD drug TQC3721, and Huadong Medicine’s IND approval for CDH17-targeting ADC HDM2017.
